Should I buy or sell Abcam stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ABCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares. View ABCM analyst ratings or view top-rated stocks .

What is Abcam's stock price target for 2024?

5 Wall Street analysts have issued 12 month price objectives for Abcam's stock. Their ABCM share price targets range from $23.00 to $23.00. On average, they anticipate the company's share price to reach $23.00 in the next year. This suggests that the stock has a possible downside of 4.1%. View analysts price targets for ABCM or view top-rated stocks among Wall Street analysts .

What ETFs hold Abcam's stock?

ETFs with the largest weight of Abcam (NASDAQ:ABCM) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ) . iShares Biotechnology ETF (IBB) .

Abcam (ABCM) raised $149 million in an initial public offering on Thursday, October 22nd 2020. The company issued 9,000,000 shares at $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair served as the underwriters for the IPO.

NASDAQ:ABCM

Abcam (ABCM) Stock Price, News & Analysis

→ Will this $2 AI stock double overnight? (From Behind the Markets) (Ad)

Free ABCM Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $23.99
▼
$23.99
50-Day Range: $23.07
▼
$23.99
52-Week Range: $12.48
▼
$25.32

Volume: 3,300 shs
Average Volume: 3.08 million shs
Market Capitalization: $5.50 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.00

Stock Analysis Analyst Forecasts Headlines Ownership Short Interest Social Media

Get Abcam alerts:

Ad Behind the Markets

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

Click here to learn more >>>

About Abcam Stock (NASDAQ:ABCM)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.

Ad Behind the Markets

The #1 Opportunity of the decade?

It's no wonder the Department of Defense is heavily invested in this technology. And why The Pentagon is pouring $20 billion into it.

Click here to learn more >>>

ABCM Stock News Headlines

February 27, 2024 | seekingalpha.com

Tracking George Soros's 13F Portfolio - Q4 2023 Update

January 18, 2024 | seekingalpha.com

Headwaters Capital Q4 2023 Investor Letter

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

December 8, 2023 | finance.yahoo.com

Abcam plc (ABCM) Interactive Stock Chart - Yahoo Finance

November 17, 2023 | markets.businessinsider.com

Abcam-Danaher Deal Receives All Identified Clearances - Quick Facts

November 15, 2023 | finance.yahoo.com

Here’s Headwaters Capital’s Perspective on Abcam plc (ABCM) Acquisition

November 6, 2023 | tmcnet.com

Shareholders of Abcam Approve Proposed Acquisition by Danaher

November 1, 2023 | benzinga.com

Statement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaign

April 19, 2024 | Behind the Markets (Ad)

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

November 1, 2023 | finanznachrichten.de

Abcam plc: Leading Proxy Advisor, ISS, Recommends Shareholders Vote "FOR" Danaher Corporation's Proposed Acquisition of Abcam

October 23, 2023 | stockhouse.com

Leading Independent Proxy Advisor Glass Lewis Joins ISS in Recommending Shareholders Vote "FOR" Danaher Corporation's Proposed Acquisition of Abcam

October 19, 2023 | finance.yahoo.com

She Blinded Me with Science – ISS Makes Schoolboy Error on Abcam Deal

October 17, 2023 | finance.yahoo.com

Leading Proxy Advisor, ISS, Recommends Shareholders Vote "FOR" Danaher Corporation’s Proposed Acquisition of Abcam

October 16, 2023 | markets.businessinsider.com

Jonathan Milner Issues Statement Responding to ISS Report

October 16, 2023 | msn.com

Abcam holders should vote for sale to Danaher, proxy adviser ISS says (update)

October 16, 2023 | finance.yahoo.com

Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company

October 9, 2023 | markets.businessinsider.com

Abcam (ABCM) Gets a Hold from RBC Capital

October 5, 2023 | msn.com

GMED or ABCM: Which Is the Better Value Stock Right Now?

October 5, 2023 | finanznachrichten.de

Abcam plc: Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share

September 21, 2023 | finance.yahoo.com

Headwaters Capital Calls Out Fishy Bid for Abcam from Danaher in Letter to Stakeholders – Exclusive

September 15, 2023 | msn.com

Abcam holder, founder Jonathan Milner opposes Danaher acquisition (update)

September 14, 2023 | benzinga.com

Abcam plc Statement on Dr. Jonathan Milner's Announcement

September 14, 2023 | msn.com

Abcam holder, founder Jonathan Milner opposes Danaher acquisition

August 31, 2023 | finance.yahoo.com

Abcam plc Interim Results for the Six-Month Period Ended 30 June 2023

August 30, 2023 | msn.com

Abcam cut to market perform at Leerink, sees no antitrust risk

August 29, 2023 | msn.com

Abcam deal price may have been hurt by antitrust concerns - report (update)

August 29, 2023 | benzinga.com

ABCAM INVESTOR ALERT by the Former Attorney...

See More Headlines

Receive ABCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:ABCM
CUSIP: N/A
CIK: 1492074
Web: www.abcam.com
Phone: 44-0-12-2369-6000
Fax: N/A
Employees: 1,760
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $23.00
High Stock Price Target: $23.00
Low Stock Price Target: $23.00
Potential Upside/Downside: -4.1%
Consensus Rating: Hold
Rating Score (0-4): 2.20
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: 54.52
P/E Growth: 2.19
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.35
Quick Ratio: 1.00

Sales & Book Value

Annual Sales: $379.70 million
Price / Sales: 14.49
Cash Flow: $0.60 per share
Price / Cash Flow: 40.17
Book Value: $3.92 per share
Price / Book: 6.12

Miscellaneous

Outstanding Shares: 229,272,000
Free Float: 213,842,000
Market Cap: $5.50 billion
Optionable: Not Optionable
Beta: 0.86

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Alan Thomas Hirzel BS (Age 55)
M.B.A., M.S., CEO & Executive Director
Comp: $1.18M
Mr. Michael Shaun Baldock B.A. (Age 59)
CFO & Director
Comp: $876.48k
Marc Leigh Russell Perkins
General Counsel & Company Secretary
Emma Sceats
Senior Vice President of Sales & Marketing
Mr. Nick Skinner
Senior Vice President of Human Resources
Ms. Alejandra Solache Ph.D.
Senior Vice President of Research & Development
Mr. John Baker
Senior Vice President of Supply Chain & Manufacturing
Juan Carlos Sacristan
Senior Vice President of Data & Digital

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ABCM Stock Analysis - Frequently Asked Questions

Should I buy or sell Abcam stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ABCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABCM, but not buy additional shares or sell existing shares.
View ABCM analyst ratings or view top-rated stocks.
What is Abcam's stock price target for 2024?: 5 Wall Street analysts have issued 12 month price objectives for Abcam's stock. Their ABCM share price targets range from $23.00 to $23.00. On average, they anticipate the company's share price to reach $23.00 in the next year. This suggests that the stock has a possible downside of 4.1%.
View analysts price targets for ABCM or view top-rated stocks among Wall Street analysts.
What ETFs hold Abcam's stock?: ETFs with the largest weight of Abcam (NASDAQ:ABCM) stock in their portfolio include Invesco Nasdaq Biotechnology ETF (IBBQ).iShares Biotechnology ETF (IBB).
When did Abcam IPO?: Abcam (ABCM) raised $149 million in an initial public offering on Thursday, October 22nd 2020. The company issued 9,000,000 shares at $16.52 per share. Morgan Stanley, BofA Securities, SVB Leerink, Lazard and William Blair served as the underwriters for the IPO.

This page (NASDAQ:ABCM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Abcam (ABCM) Stock Price, News & Analysis

About Abcam Stock (NASDAQ:ABCM)

ABCM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ABCM Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info